Mangalam Drugs and Organics Ltd: Intrinsic Value & Share Price Analysis

Q: What is the current share price and 52-week range of Mangalam Drugs and Organics Ltd?

Mangalam Drugs and Organics Ltd is trading at 30.40 as of 01 September 2026, with a FY2026-2027 high of 86.0 and low of 22.7. The stock is currently near its 52-week low. Market cap stands at 48.2 Cr..

Q: Is Mangalam Drugs and Organics Ltd financially healthy?

Key indicators: ROCE of 14.0 % is moderate. Dividend yield is 0.00 %.

Q: Is Mangalam Drugs and Organics Ltd profitable and how is the profit trend?

Mangalam Drugs and Organics Ltd reported a net profit of 7 Cr in Mar 2025 on revenue of 318 Cr. Compared to 20 Cr in Mar 2022, the net profit shows a declining trend.

Fair Value

₹278.15Undervalued by 814.97%vs CMP ₹30.40

P/E (15.0) × ROE (34.8%) × BV (₹65.30) × DY (2.00%)

Defaults: P/E=15

₹108.27Undervalued by 256.15%vs CMP ₹30.40

MoS: +71.9% (Strong)Confidence: 56/100 (Moderate)Models: 6 Under, 1 Over

Model	Category	Value	Weight	Signal
PE-ROE	Earnings	₹138.42	26%	Under (+355.3%)
Graham Number	Earnings	₹80.13	23%	Under (+163.6%)
Net Asset Value	Assets	₹64.96	10%	Under (+113.7%)
EV/EBITDA	Enterprise	₹261.74	13%	Under (+761%)
Earnings Yield	Earnings	₹43.70	10%	Under (+43.8%)
ROCE Capital	Returns	₹18.26	10%	Over (-39.9%)
Revenue Multiple	Revenue	₹100.28	8%	Under (+229.9%)
Consensus (7 models)		₹108.27	100%	Undervalued

Key Drivers: EPS CAGR -50.2% drags value — could be higher if earnings stabilize. | Wide model spread (₹18–₹262) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -50.2% · Defaults: P/E=15

*Investments are subject to market risks

Analyst Summary

Mangalam Drugs and Organics Ltd operates in the Pharmaceuticals segment, NSE: MANGALAM | BSE: 532637, current market price is ₹30.40, market cap is 48.2 Cr.. At a glance, ROE is 34.8 %, ROCE is 14.0 %, book value is 65.3, dividend yield is 0.00 %. The latest intrinsic value estimate is ₹108.27, which is about 256.2% above the current price, so the page currently reads as potentially undervalued rather than fully priced. On operating trend, latest reported sales are about ₹318 Cr versus the prior period change of -13.8%, while latest net profit is about ₹7 Cr with a prior-period change of 177.8%. The 52-week range shown on this page is 86.0/22.7, which helps frame where the current quote sits within its recent trading band. Business context: About the Company - Qualitative AnalysisMangalam Drugs and Organics Ltd. is a Public Limited Listed company incorporated on 18/04/1972 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Numb…

This summary is generated from the stock page data available for Mangalam Drugs and Organics Ltd: Intrinsic Value & Share Price Analysis and is refreshed automatically when the underlying metrics change.

Investment Snapshot

Mangalam Drugs and Organics Ltd scores 49/100 (Average)

Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison

Stock Health65/100 · Strong

ROCE 14.0% GoodROE 34.8% ExcellentD/E 0.64 ModerateInterest Coverage 0.0x RiskyProfitable 4/5 years Consistent

Smart Money50/100 · Moderate

FII holding stable No changePromoter holding at 35.7% Stable

Earnings Quality60/100 · Moderate

OPM stable around 8% SteadyWorking capital: 13 days (improving) Efficient

Quarterly Momentum15/100 · Weak

Revenue (4Q): -31% YoY DecliningProfit (4Q): -397% YoY DecliningOPM: -2.5% (down 12.4% YoY) Margin pressure

Industry Rank40/100 · Moderate

ROCE 14.0% vs industry 25.3% Below peersROE 34.8% vs industry 18.4% Above peers3Y sales CAGR: -11% Shrinking

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily.

Share Price and Basic Stock Data

Last Updated: August 25, 2026, 7:21 am

Market Cap	48.2 Cr.
Current Price	30.4
Intrinsic Value	₹108.27
High / Low	86.0/22.7
Stock P/E
Book Value	65.3
Dividend Yield	0.00 %
ROCE	14.0 %
ROE	34.8 %
Face Value	10.0
PEG Ratio	0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Mangalam Drugs and Organics Ltd

Competitors

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Lactose (India) Ltd	125 Cr.	99.0	137/76.0	18.0	51.5	0.00 %	11.3 %	9.81 %	10.0
MPS Pharmaa Ltd	3.80 Cr.	1.99	2.08/1.57		0.04	0.00 %	13.1 %	177 %	10.0
Gujarat Themis Biosyn Ltd	4,415 Cr.	405	479/225	90.7	26.4	0.16 %	17.9 %	17.4 %	1.00
Gujarat Terce Laboratories Ltd	27.8 Cr.	35.7	59.8/29.0	12.5	12.5	0.00 %	39.2 %	30.2 %	10.0
Gujarat Inject (Kerala) Ltd	168 Cr.	11.5	14.3/1.90	56.2	0.81	0.00 %	22.9 %	16.6 %	1.00
Industry Average	23,072.45 Cr	1,307.39		54.56	215.82	0.36%	25.34%	18.37%	6.02

All Competitor Stocks of Mangalam Drugs and Organics Ltd

Quarterly Result

Metric	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	63.32	91.11	87.46	81.56	97.34	102.24	76.53	79.94	88.71	73.04	57.35	49.54	58.49
Expenses	56.84	90.87	90.94	79.37	90.36	90.54	68.34	71.25	79.94	62.88	61.86	52.37	59.96
Operating Profit	6.48	0.24	-3.48	2.19	6.98	11.70	8.19	8.69	8.77	10.16	-4.51	-2.83	-1.47
OPM %	10.23%	0.26%	-3.98%	2.69%	7.17%	11.44%	10.70%	10.87%	9.89%	13.91%	-7.86%	-5.71%	-2.51%
Other Income	0.13	0.29	0.02	0.03	0.00	0.05	0.02	0.14	0.13	0.21	0.00	0.03	0.11
Interest	3.22	3.43	3.41	3.24	3.31	3.95	3.75	3.67	3.49	4.03	4.04	5.03	4.05
Depreciation	2.88	2.75	3.42	3.73	3.62	3.86	3.87	3.97	3.93	4.61	4.38	4.53	4.37
Profit before tax	0.51	-5.65	-10.29	-4.75	0.05	3.94	0.59	1.19	1.48	1.73	-12.93	-12.36	-9.78
Tax %	15.69%	-22.30%	-7.29%	-25.05%	-920.00%	9.90%	-355.93%	-125.21%	5.41%	90.75%	6.19%	-41.42%	0.00%
Net Profit	0.43	-4.39	-9.54	-3.56	0.50	3.55	2.68	2.69	1.40	0.15	-13.73	-7.25	-9.78
EPS in Rs	0.27	-2.77	-6.03	-2.25	0.32	2.24	1.69	1.70	0.88	0.09	-8.67	-4.58	-6.18

Last Updated: February 5, 2026, 2:05 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 24, 2026, 11:46 pm

Metric	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	123	221	295	299	269	228	282	380	451	372	369	318	238
Expenses	113	200	257	252	222	218	259	327	402	347	351	282	237
Operating Profit	10	20	38	47	47	10	24	53	49	26	17	36	1
OPM %	8%	9%	13%	16%	17%	4%	8%	14%	11%	7%	5%	11%	1%
Other Income	0	0	0	-0	1	0	1	5	0	0	0	0	0
Interest	10	10	9	10	12	9	10	9	11	13	14	15	17
Depreciation	4	4	4	5	7	7	8	9	10	11	15	16	18
Profit before tax	-4	6	24	31	29	-6	6	40	28	2	-11	5	-33
Tax %	-22%	-2%	33%	29%	32%	40%	-32%	29%	29%	43%	-18%	-39%
Net Profit	-3	6	16	22	20	-8	8	28	20	1	-9	7	-31
EPS in Rs	-2.31	4.66	11.15	14.08	12.57	-5.07	5.21	17.67	12.42	0.80	-5.72	4.37	-19.34
Dividend Payout %	0%	0%	0%	0%	4%	0%	0%	0%	0%	0%	0%	0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	300.00%	166.67%	37.50%	-9.09%	-140.00%	200.00%	250.00%	-28.57%	-95.00%	-1000.00%	177.78%
Change in YoY Net Profit Growth (%)	0.00%	-133.33%	-129.17%	-46.59%	-130.91%	340.00%	50.00%	-278.57%	-66.43%	-905.00%	1177.78%

Mangalam Drugs and Organics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

No data available for the compounded sales growth chart.

Balance Sheet

Last Updated: July 7, 2026, 1:00 am

Month	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	13	14	16	16	16	16	16	16	16	16	16	16
Reserves	16	47	70	88	80	88	115	135	136	127	133	87
Borrowings	78	60	66	69	65	52	70	88	89	107	96	105
Other Liabilities	63	38	38	54	50	75	64	90	117	108	114	99
Total Liabilities	170	160	190	227	211	231	264	328	358	357	359	308
Fixed Assets	53	54	93	102	103	101	118	135	142	147	156	152
CWIP	0	5	0	0	0	1	6	6	9	8	3	0
Investments	0	0	2	0	0	0	0	0	0	0	0	0
Other Assets	117	100	95	125	107	128	140	188	206	202	201	156
Total Assets	170	160	190	227	211	231	264	328	358	357	359	308

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity +	14	22	43	25	22	31	28	26	38	12	43	4
Cash from Investing Activity +	-4	-11	-39	-16	-9	-7	-31	-27	-22	-18	-19	-12
Cash from Financing Activity +	-10	-11	-3	-9	-11	-23	3	3	-17	6	-22	6
Net Cash Flow	1	-0	0	-0	1	0	-1	1	-1	-0	2	-2
Free Cash Flow	10	11	3	9	12	24	-4	-2	16	-6	23	-8
CFO/OP	69%	68%	107%	66%	223%	129%	69%	70%	148%	71%	119%	-30%

Free Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	10.00	-58.00	-22.00	-19.00	-22.00	-55.00	-28.00	-17.00	-39.00	-63.00	-90.00	-60.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	88	73	37	45	61	28	52	52	38	46	28	45
Inventory Days	170	134	85	69	132	175	121	85	139	200	185	303
Days Payable	97	128	37	38	82	77	106	63	65	139	124	199
Cash Conversion Cycle	161	79	85	75	111	126	67	74	112	107	88	148
Working Capital Days	29	26	32	19	31	21	10	23	43	38	18	13
ROCE %	6%	16%	29%	31%	25%	2%	11%	27%	18%	6%	1%	8%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	50.31%	50.31%	50.31%	50.31%	50.30%	50.30%	50.30%	50.30%	50.30%	35.64%	35.65%	35.65%
FIIs	0.10%	0.10%	0.26%	0.21%	0.11%	0.11%	0.47%	0.53%	0.11%	0.13%	0.32%	0.11%
Public	49.59%	49.59%	49.42%	49.47%	49.58%	49.58%	49.23%	49.16%	49.57%	64.22%	64.03%	64.24%
No. of Shareholders	17,978	18,610	19,173	19,312	19,508	19,679	19,697	19,728	19,881	21,227	25,140	24,465

Shareholding Pattern Chart

No. of Shareholders

Mangalam Drugs and Organics Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 25	Mar 24
FaceValue	10.00	10.00
Basic EPS (Rs.)	4.25	-5.73
Diluted EPS (Rs.)	4.25	-5.73
Cash EPS (Rs.)	14.74	3.52
Book Value[Excl.RevalReserv]/Share (Rs.)	94.12	85.79
Book Value[Incl.RevalReserv]/Share (Rs.)	94.12	85.79
Revenue From Operations / Share (Rs.)	201.05	232.87
PBDIT / Share (Rs.)	22.95	11.05
PBIT / Share (Rs.)	12.46	1.80
PBT / Share (Rs.)	3.02	-7.00
Net Profit / Share (Rs.)	4.25	-5.73
NP After MI And SOA / Share (Rs.)	4.25	-5.73
PBDIT Margin (%)	11.41	4.74
PBIT Margin (%)	6.19	0.77
PBT Margin (%)	1.50	-3.00
Net Profit Margin (%)	2.11	-2.46
NP After MI And SOA Margin (%)	2.11	-2.46
Return on Networth / Equity (%)	4.51	-6.68
Return on Capital Employeed (%)	11.27	1.67
Return On Assets (%)	1.83	-2.71
Long Term Debt / Equity (X)	0.06	0.09
Total Debt / Equity (X)	0.54	0.64
Asset Turnover Ratio (%)	0.90	0.00
Current Ratio (X)	1.04	1.07
Quick Ratio (X)	0.31	0.31
Inventory Turnover Ratio (X)	2.43	0.00
Interest Coverage Ratio (X)	2.43	1.26
Interest Coverage Ratio (Post Tax) (X)	1.45	0.34
Enterprise Value (Cr.)	196.06	233.41
EV / Net Operating Revenue (X)	0.61	0.63
EV / EBITDA (X)	5.40	13.34
MarketCap / Net Operating Revenue (X)	0.36	0.39
Price / BV (X)	0.78	1.08
Price / Net Operating Revenue (X)	0.36	0.39
EarningsYield	0.05	-0.06

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

[display_about_company_data title=”About the Company – Qualitative Analysis”]

FAQ

What is the intrinsic value of Mangalam Drugs and Organics Ltd and is it undervalued?

As of 01 September 2026, Mangalam Drugs and Organics Ltd's intrinsic value is ₹108.27, which is 256.15% higher than the current market price of ₹30.40, suggesting the stock is undervalued. This is calculated using the PE ratio method factoring in ROE (34.8 %), book value (₹65.3), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Mangalam Drugs and Organics Ltd?

Mangalam Drugs and Organics Ltd is trading at ₹30.40 as of 01 September 2026, with a FY2026-2027 high of ₹86.0 and low of ₹22.7. The stock is currently near its 52-week low. Market cap stands at ₹48.2 Cr..

How does Mangalam Drugs and Organics Ltd's P/E ratio compare to its industry?

Mangalam Drugs and Organics Ltd has a P/E ratio of , which is below the industry average of 54.56. This is broadly in line with or below the industry average.

Is Mangalam Drugs and Organics Ltd financially healthy?

Key indicators for Mangalam Drugs and Organics Ltd: ROCE of 14.0 % is moderate; ROE of 34.8 % shows strong shareholder returns. Dividend yield is 0.00 %.

Is Mangalam Drugs and Organics Ltd profitable and how is the profit trend?

Mangalam Drugs and Organics Ltd reported a net profit of ₹7 Cr in Mar 2025 on revenue of ₹318 Cr. Compared to ₹20 Cr in Mar 2022, the net profit shows a declining trend.

Does Mangalam Drugs and Organics Ltd pay dividends?

Mangalam Drugs and Organics Ltd has a dividend yield of 0.00 % at the current price of ₹30.40. The company is currently not paying meaningful dividends.